Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2385 • 2014 ACR/ARHP Annual Meeting
Reasons for Non-Vaccination in Rheumatoid Arthritis and Spondyloarthritis Patients
Charlotte Hua¹, Jacques Morel², Bernard Combe¹ and Cédric Lukas^1,3, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatic diseases are at increased risk of infections when compared to healthy controls. Despite the fact that part of these infections…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting
Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Leslie R. Harrold¹, George W. Reed^1,2, Chitra Karki³, Robert Magner¹, Ashwini Shewade⁴, Ani John⁴, Joel M. Kremer⁵ and Jeffrey D. Greenberg^3,6, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC., Southborough, MA, ³Corrona, LLC, Southborough, MA, ⁴Genentech, Inc, South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…
Abstract Number: 129 • 2014 ACR/ARHP Annual Meeting
Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice
Petra Hanova¹, Jakub Zavada¹, Jana Hurnakova¹, Martin Klein¹, Olga Sleglova¹, Marta Olejarova¹, Martin Komarc², Ladislav ŠEnolt¹ and Karel Pavelka³, ¹Institute of Rheumatology, Charles University, 1st Medical Faculty, Prague, Czech Republic, ²Institute of Biophysics and Informatics, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: To evaluate if the 7-joint ultrasound scoring system (US7) is able to find synovitis in patients in remission of RA. Methods: Patients with rheumatoid…
Abstract Number: 2165 • 2014 ACR/ARHP Annual Meeting
Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe?
Fanlei Hu¹, Chunqing Guo², Xiang-Yang Wang² and Zhanguo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose Although myeloid-derived suppressor cells (MDSCs) have been linked to T-cell tolerance, their role in rheumatoid arthritis (RA) remains exclusive. Here, we investigated the potential…
Abstract Number: 1450 • 2014 ACR/ARHP Annual Meeting
Spironolactone As a Novel DMARD in Rheumatoid Arthritis
Inderjeet Verma¹, Pawan Krishan² and Ashit Syngle³, ¹Deptt. of Pharmaceutical Sciences & Drug Resaerch, Punjabi University Patiala, India, Chandigarh, India, ²Deptt. of Pharmaceutical Sciences & Drug Research, Punjabi University Patiala, India, Patiala, India, ³Cardio Rheuma, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India
Background/Purpose: Synthetic disease-modifying antirheumatic drugs (DMARDs) though effective have limitations often requiring use of expensive parenteral biologic DMARDs in Rheumatoid Arthritis (RA). Hence there is…
Abstract Number: 517 • 2014 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results
Boulos Haraoui¹, Shahin Jamal², Vandana Ahluwalia³, Tarang Manchanda⁴ and Majed Khraishi⁵, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³William Osler Health Center, Brampton, ON, Canada, ⁴Hoffmann-La Roche Canada, Mississauga, ON, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada
Background/Purpose Tocilizumab (TCZ) has been approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or as combination with disease-modifying antirheumatic drugs…
Abstract Number: 126 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Versus Symptomatic Ankle Joints in Rheumatoid Arthritis: A High Resolution B-Mode and Power Doppler Ultrasound Study
Mohammed Alsuwaidi¹, Boris P. Ehrenstein¹, Wolfgang Hartung¹ and Martin Fleck², ¹Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ²Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany
Background/Purpose: Despite a crucial role for RA patients’ mobility, the ankle joints are frequently clinically neglected, and omitted in activity scoring systems including DAS 28.…
Abstract Number: 2132 • 2014 ACR/ARHP Annual Meeting
What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity?
Violaine Foltz¹, Lisa Biale², Frederique Gandjbakhch¹, Laure Gossec¹, Pierre Bourgeois¹, Benjamin Granger³ and Bruno Fautrel¹, ¹Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France, ²Rheumatology, Instruction des Armées Begin hospital, Saint-mande, France, ³Departement de santé publique, information medicale et biostatistiques, unite biotstatistiques, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose Persistent inflammation on Power Doppler (PD) by ultrasound (US) was associated with relapse and structural progression after one year of follow up in a…
Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting
Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness
Kuljeet Bhamra¹, Catherine Swales¹, Matthew Seymour¹, Catherine McClinton¹ and Peter C. Taylor², ¹Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom
Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 124 • 2014 ACR/ARHP Annual Meeting
Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis
Jackie L. Nam, Laura Hunt, Elizabeth M.A. Hensor, Philip G. Conaghan, Richard J. Wakefield and Paul Emery, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose The use of musculoskeletal ultrasound is increasing in rheumatology practice. Recently we have shown that use of power Doppler signal (PD) on ultrasound in…
Abstract Number: 2030 • 2014 ACR/ARHP Annual Meeting
Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study
Mette Axelsen¹, Trine Bay Laurberg¹, Robin Christensen², Ulrich Fredberg³ and Torkell Ellingsen^4,5,6, ¹Silkeborg Hospital, Silkeborg, Denmark, ²Rheumatology, MSU, The Parker Institute, Copenhagen University Hospital, Frederiksberg, Denmark, ³Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁴Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁵The Danish National Registry DANBIO, Odense, Denmark, ⁶Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark
Background/Purpose Finding prognostic factors for treatment failure on synthetic disease modifying antirheumatic drugs (DMARD) in early treatment naive rheumatoid arthritis (RA) is a challenge. The…
Abstract Number: 1430 • 2014 ACR/ARHP Annual Meeting
IMPACT of Initiative to Control Cardiovascular Risk Factors in Collaboration with LOCAL Doctors in Patients with Rheumatoid Arthritis
Andrea Zacarias Crovato¹, Javier Narváez², Joan Miquel Nolla³, Jesús Rodríguez-Moreno⁴, Montserrat Jordana¹ and Carmen Gomez Vaquero³, ¹Hospital Universitari de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with cardiovascular risk (CVR) with an increased prevalence of cardiovascular events and cardiovascular mortality than the general population. Good…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].